Imeroprubart
Monoclonal antibody
Also known as IMVT-1402
Evidence outlook · registrational
Myasthenia Gravis: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-12.
Also in development:Rheumatoid Arthritis · Phase 2Graves' Disease · Phase 2Chronic Inflammatory Demyelinating Polyneuropathy · Phase 2Sjögren's Disease · Phase 2
Development in Cutaneous Lupus Erythematosus stopped (2026-09-23) after a negative readout. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07039916 NCT07039916 · Myasthenia Gravis Registry: NCT07039916 | 3 | Change from Baseline in MG-ADL Score for Antibody-positive Participants (Baseline to Week 12) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Chronic Inflammatory Demyelinating Polyneuropathy: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Imeroprubart: this drug | Phase 2 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa (Vyvgart) | Approved(overall) | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Riliprubart | Phase 3 | Monoclonal antibody | Complement C1s | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-411 | —(overall) | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Imeroprubart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
May 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (3)
June 2028 (1)
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent